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 2 
Abstract 30 
Background: CAH due to 21-hydroxylase deficiency leads to accumulation of steroid precursors and 31 
adrenal androgens. These steroids may have a biological effect on the steroid receptor with clinical 32 
consequences on diagnostics and treatment in CAH patients.  Therefore, we analysed the effect of 33 
accumulated steroids (17 hydroxyprogesterone (17OHP), progesterone, androstenedione, testosterone) 34 
on aldosterone mediated transactivation of the human mineralocorticoid receptor (hMR).  35 
Methods: A transactivation assay using transiently transfected COS7 cells was employed. Cells were 36 
co-transfected with hMR-cDNA, MMTV-luciferase and renilla-luciferase expression vectors. 37 
Transfected cells were incubated with six different steroid concentrations in addition to aldosterone 38 
(10-10 mol/l). Luciferase and renilla activities were measured to quantify hMR transactivation.  39 
Results: Linear regression analysis showed statistically significant linear inhibition of transactivation 40 
of the hMR by 10-10 mol/l aldosterone in the presence of increasing 17OHP (F(1,5)=11.34, p=0.019) 41 
and progesterone (F(1,5)=11.08, p=0.021) concentrations. In contrast neither androstenedione nor 42 
testosterone affected hMR transactivation by aldosterone at a concentration of 10-10 mol/l.  43 
Conclusion: Our study shows for the first time that neither androstenedione nor testosterone has a 44 
biological effect on  aldosterone-mediated transactivation of the hMR. 17OHP and progesterone have 45 
an anti-mineralocorticoid effect in vitro that may clinically lead to an increased requirement of 46 
mineralocorticoids in poorly controlled CAH patients. 47 
 48 
49 
 3 
Introduction 50 
Congenital adrenal hyperplasia (CAH) is a group of disorders affecting adrenal steroidogenesis. The 51 
incidence of classic CAH varies between 1 in 10,000 to 1 in 15,000 live births in most Caucasian 52 
populations.[1] In about 95% of the cases CAH is caused by 21-hydroxylase deficiency, [2] resulting 53 
in impaired adrenal synthesis of cortisol. Cortisol deficiency triggers a counter-regulatory increase in 54 
pituitary ACTH secretion leading to accumulation of adrenal steroid precursors before the deficient 55 
enzymatic step and increased adrenal androgen production. 21-hydroxylase converts 17-56 
hydroxyprogesterone (17OHP) to 11-deoxycortisol, the penultimate step in cortisol synthesis. Hence 57 
17OHP accumulates and is used as a marker for 21-hydroxylase deficiency. 58 
Classic CAH is commonly subdivided in the salt wasting (SW) and simple virilizing (SV) forms 59 
depending on the residual enzymatic activity. SW patients have no residual 21-hydroxylase activity 60 
leading to severe salt loss, typically after the first week of life, and prenatal virilization of the female 61 
external genitalia. Patients with the SV form of CAH have a residual enzyme activity of 1-2 % and 62 
usually have sufficient aldosterone production to prevent severe salt loss whereas glucocorticoid 63 
synthesis is severely impaired. In both SW and SV forms elevated adrenal androgens cause prenatal 64 
virilization of the female external genitalia and postnatal androgen excess in both sexes. [2,3] Current 65 
treatment of CAH consists of lifelong glucocorticoid and, if necessary, also mineralocorticoid 66 
treatment.[4] Treatment with glucocorticoids restores feedback within the hypothalamus-pituitary-67 
adrenal axis, consequently achieving down-regulation of adrenal androgen production. However, in 68 
many patients supraphysiological doses of glucocorticoids are needed to normalize androgen levels. 69 
Untreated and poorly controlled CAH patients are characterized by elevated levels of steroid hormone 70 
precursors, including progesterone and 17OHP, and androgens such as androstenedione and 71 
testosterone.[3,5-8] It has been shown that progesterone and 17OHP have antagonistic properties on 72 
the human mineralocorticoid receptor (hMR), and therefore may contribute to the mineralocorticoid 73 
deficiency in classic CAH patients. [9] The aim of our study was to evaluate the effects of 17OHP, 74 
progesterone, androstenedione and testosterone on the aldosterone mediated transactivation and 75 
translocalisation of the hMR. Furthermore, we studied the effect of the frequent mineralocorticoid 76 
receptor (MR) p.Ile180Val single nucleotide polymorphism (SNP) on transactivation of the hMR.  77 
 4 
Material and Methods 78 
Construction of plasmids 79 
The hMR cDNA was PCR amplified from the previously used pcDNA3.1-NR3C2 construct[10] using 80 
specific primers with HindIII and EcoRV restriction sites for directional cloning into pcDNA6/V5-81 
His-B vector (Invitrogen Corp., Carlsbad, CA, USA). The p.Ile180Val SNP was recreated in the 82 
pcDNA6-hMR construct by site-directed mutagenesis using the QuikChange XL Site-Directed 83 
Mutagenesis Kit according to the manufacturer’s protocol (Stratagene, Amsterdam, The Netherlands). 84 
The correct insertion of the hMR construct and the p.Ile180Val SNP as well as the integrity of the 85 
cDNA was checked by direct DNA sequencing. For intracellular localization assays Green 86 
Fluorescent Protein (GFP), an autofluorescent genetic reporter, was cloned into pcDNA6. The hMR 87 
cDNA and the hMR p.Ile180Val (hMR-I180V) construct were cloned into the pcDNA6-GFP vector 88 
using the same restriction enzymes as described above. 89 
 90 
In vitro transactivation assays 91 
Transactivation of hMR and hMR-I180V by different concentrations of aldosterone was investigated 92 
using a MMTV-luciferase assay. Approximately 2.5 × 104 COS-7 cells were grown in 500 ml of 93 
Dulbecco’s minimal essential medium (DMEM) High Glucose (4,5 g/l) with L-Glutamine (PAA 94 
Laboratories GmbH, Pasching, Austria) supplemented with 10% fetal bovine serum (PAA 95 
Laboratories GmbH) and Penicillin/Streptomycin (PAA Laboratories GmbH) in 24-well plates and 96 
transiently transfected 24 h after seeding using FuGene® HD transfection reagent (Roche Applied 97 
Sciences, Burgess Hill, United Kingdom). Cells were transfected with 300 ng pcDNA6-V5/HisB-98 
hMR or pcDNA6-V5/HisB-hMR variant (p.Ile180Val) in the presence of 300 ng of a mouse 99 
mammary tumor virus (MMTV)-luciferase reporter construct (MMTV-luc) driving the firefly 100 
luciferase gene. Co-transfection with 50 ng pRL-TK (Promega, Madison, WI, USA), a renilla 101 
luciferase vector, was performed to normalize data for transfection efficiency. In each set of 102 
experiments 3 wells with COS-7 cells were co-transfected with 300 ng of pcDNA-hMR and 300 ng of 103 
pGL3-Basic (Promega) for data normalization and interassay comparison purposes as pGL3-Basic 104 
contains a coding region for firefly luciferase for monitoring transcriptional activity in transfected 105 
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cells. Two days after transfection cells were treated with aldosterone (Sigma Aldrich, Gillingham, 106 
United Kingdom) for 24 hours in different concentrations (final concentrations made up in total of 107 
500 uL full DMEM media: 10-6, 10-8, 10-10, 10-12, 10-14 mol/l) , or in a 10-10 mol/l concentration in 108 
addition to different concentrations of 17OHP (range 5-1000 nmol/l), progesterone (2.5-100 nmol/l), 109 
androstenedione (1-250 nmol/l) or testosterone (0.5-60 nmol/l) (Sigma Aldrich). Concentrations of 110 
17OHP, progesterone, androstenedione and testosterone used in the assays are based on biochemical 111 
findings in CAH patients.[5-8] 112 
To evaluate the transactivational potential of 17OHP, progesterone, androstenedione and testosterone 113 
on the hMR in the absence of aldosterone, transfected cells were also incubated in 500 uL of full 114 
DMEM supplemented with different concentrations of these steroids. 115 
Cells were lysed in 100 uL of passive lysis buffer (Promega). Consequently   30 uL of cell lysate was 116 
used for the measurement of firefly and renilla luciferase activity, with a luminometer (Berthold, Bad 117 
Wildbad, Germany), using the Dual-Luciferase ® Reporter Assay System (Promega) according to 118 
manufacturer’s standard protocol. The hMR transactivation was calculated by the ratio of the steroid 119 
dependent (firefly) luciferase and the steroid independent renilla (luciferase). Luciferase/Renilla ratios 120 
were normalized for luciferase activity driven by pGL3-Basic. Data were normalized for the 121 
transactivation by a 10-10 mol/l aldosterone concentration and are presented as fold transactivation 122 
compared to the transactivation by 10-10 mol/l aldosterone (transactivation by 10-10 mol/l aldosterone 123 
was set as 1.0 fold transactivation). All assays were performed in triplicate – triplicate. Statistical 124 
analysis was performed using GraphPad Prism software version 5.0 (GraphPad Software, San Diego, 125 
CA, USA). Results were analyzed by both linear regression analyses and ANOVA with Bonferroni 126 
adjustment for multiple comparisons (all possible comparisons were analyzed). Differences between 127 
the hMR wild type and the p.Ile180Val construct were analyzed using a t test. A p value of < 0.05 was 128 
considered significant. 129 
 130 
Intracellular localization 131 
The transactivational potential of the hMR-GFP construct was evaluated to ensure comparable 132 
transactivational potential to the hMR construct in the presence of 10-10 M concentrations of 133 
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aldosterone.  The hMR-GFP construct was used for an intracellular localization assay. Approximately 134 
2 × 105 COS-7 cells were grown on glass coverslips in 6-well plates containing 2 mL of DMEM High 135 
Glucose (4,5 g/l) with L-Glutamine (PAA Laboratories GmbH) supplemented with charcoal stripped 136 
fetal bovine serum (Sigma Aldrich) and Penicillin/Streptomycin (PAA Laboratories GmbH). Twenty-137 
four hours after seeding, cells were transiently transfected using FuGene® HD transfection reagent 138 
(Roche Applied Sciences) with 2 μg of hMR-GFP or 2 μg of hMR-I180V-GFP. Forty-eight hours 139 
after transfection, cells were treated for 120 min with a combination of 10-10 mol/L aldosterone and 140 
different concentrations of other steroids (17OHP, progesterone, androstenedione and testosterone) to 141 
study the effect of these steroids on the intracellular localization of the receptor. Cells were washed 142 
three times in 1x phosphate buffered saline (PBS) and fixed in 1 ml 100% methanol at - 20ᵒC for 15 143 
min. Fixed cells were further washed 3 more times in 1xPBS and mounted on Vectorshield with 4’, 6-144 
diamidino-2-phenylindole (DAPI; exclusively nuclear staining). Results were obtained from three 145 
independent transfection experiments in which 150 transfected cells were classified in 4 categories: 1. 146 
Nuclear, 2. Mainly nuclear, 3. Equal nuclear and cytoplasmic, 4. Mainly cytoplasmic. Representative 147 
images were taken using confocal microscopy (Nikon Instruments Inc., Melville, NY, USA). To 148 
evaluate if treatment causes a difference in the number of cells counted as nuclear, mainly nuclear, 149 
equal nuclear or mainly cytoplasmic respectively, a one way ANOVA analysis was performed. 150 
Statistical analysis was performed using GraphPad Prism software version 5.0. 151 
152 
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Results 153 
Transactivation of the mineralocorticoid receptor by aldosterone 154 
Increasing concentrations of aldosterone caused an increase in potent transactivation of both the hMR 155 
and hMR-I180V. The dose dependent effects on the transactivation are shown in a dose response 156 
curve (Figure 1). An estimated concentration for 50% transactivation (EC-50) of the hMR of around 157 
10-10 mol/l aldosterone was calculated for both the wild type (2.4 x 10-11 mol/l) and the p.Ile180Val 158 
SNP (1.2 x 10-11 mol/l). 159 
 160 
Effect of 17OHP, progesterone, androstenedione and testosterone on hMR transactivation 161 
Increasing concentrations of 17OHP and progesterone inhibited aldosterone mediated transactivation 162 
of the hMR in a dose dependent fashion (Figure 2). Linear regression analyses showed a linear 163 
inhibition of transactivation of the hMR by 10-10 mol/l aldosterone in the presence of increasing 164 
concentrations of 17OHP (F(1,5)=11.34, p=0.019) and progesterone (F(1,5)=11.08, p=0.021). 165 
Variable concentrations of 17OHP (F(6,48)=111.9, p<0.0001) and progesterone (F(6,48)=62.11, 166 
p<0.0001) have a significant effect on transactivation of the hMR by aldosterone in the presence of 167 
10-10 mol/l aldosterone, as shown by ANOVA analyses (Supplementary table 1-2). 168 
In contrast, treatment with increasing concentrations of androstenedione and testosterone did not have 169 
any measureable effect on hMR transactivation (Figure 2). No linear effect of increasing 170 
concentrations of androstenedione (F(1,5)=0.709, p=0.438) or testosterone (F(1,5)=1,57, p=0.265) on 171 
transactivation of the hMR by aldosterone was found. 172 
In addition, ANOVA analyses showed that different concentrations of androstenedione or testosterone 173 
did not affect transactivation of the hMR by aldosterone (Supplementary table 3-4).  174 
The effect of three different concentrations of 17OHP on the aldosterone mediated transactivation of 175 
the hMR was also evaluated in the p.Ile180Val SNP construct (Figure 3). The inhibitory effect of 176 
17OHP on hMR-I180V was found to be similar to its effect on the wild type hMR (p>0.05). 177 
 178 
Intracellular localization of the hMR 179 
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The transactivation potential of both the hMR-GFP and the hMR construct were compared to assess 180 
that the GFP has not altered transactivational properties of the construct prior to performing an 181 
intracellular localization assay. The hMR-GFP construct showed to have equal transactivational 182 
properties as the hMR construct (Supplementary Figure 1). 183 
In untreated cells, the hMR was localized only in the cytoplasm or equally distributed in nucleus and 184 
cytoplasm (Figure 4A). Treatment with aldosterone for 120 minutes resulted in a clear translocation 185 
of the hMR with a predominantly nuclear localization.  186 
17OHP and progesterone did not influence the translocation of the hMR to the nucleus in the presence 187 
of aldosterone (Figure 4B). Treatment with 17OHP, progesterone, androstenedione or testosterone 188 
did not result in significant differences in the intracellular localization of the hMR. 189 
 In the presence of aldosterone, the hMR-I180V-GFP was also mainly localized in the nucleus. 190 
17OHP did not inhibit the translocation of the hMR-I180V-GFP to the nucleus in the presence of 191 
aldosterone (Figure 4C). 192 
 193 
194 
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Discussion 195 
We studied the effects of different adrenal steroid hormone precursors and androgens on the 196 
transactivational potential and localization of the human mineralocorticoid receptor. Our study shows 197 
for the first time that excess concentrations of androstenedione and testosterone do not have a 198 
biological effect on the aldosterone mediated transactivation of the hMR in vitro. Furthermore, 199 
17OHP and progesterone have a strong anti-mineralocorticoid effect in vitro, which confirms previous 200 
findings.[9] This study highlights the anti-mineralocorticoid effect of elevated 17OHP concentrations 201 
as found in poorly controlled CAH patients. 202 
These findings may have important implications for the clinical care provision. Based on our results, 203 
it can be suggested that elevated 17OHP and progesterone concentrations are likely to have an adverse 204 
effect on the mineralocorticoid effect in untreated and poorly treated CAH. This may potentially lead 205 
to increased requirement of mineralocorticoids and sub-optimal control. In contrast, elevated 206 
androgens did not influence the mineralocorticoid transactivation in vitro. We therefore hypothesize 207 
that elevated androgens per se do not have a clinical relevant effect on mineralocorticoid treatment in 208 
the clinical care of CAH.  209 
The current treatment strategy is based on normalizing of adrenal androgens to prevent adverse effects 210 
of hyperandrogenism. Slightly elevated 17OHP concentrations are generally accepted because of the 211 
possible side effects of high dosages of glucocorticoids needed to achieve physiological 17OHP 212 
concentrations. Based on our results it can be suggested that lowering of highly elevated 17OHP 213 
concentrations may also have an additional positive effect  on the dosage of mineralocorticoid 214 
treatment and consequently decrease the potential risk of adverse effects of mineralocorticoid 215 
treatment such as hypertension.  Unfortunately, supraphysiological doses of glucocorticoids are 216 
generally necessary to lower 17OHP levels that may lead to adverse effects and long term 217 
complications. Therefore, the treatment goal in CAH patients is normalization of adrenal androgens 218 
with slightly elevated 17OHP levels. [4] Elevated renin levels may indicate the need of higher 219 
mineralocorticoid doses. However, based on our data elevated renin concentrations may also reflect 220 
the anti-mineralocorticoid effect of elevated 17OHP concentrations. A fine balance between the use of 221 
supraphysiological dosages of glucocorticoids, mineralocorticoid treatment and normalizing 17OHP 222 
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levels has to be achieved to prevent long-term complication of overtreatment with glucocorticoids on 223 
one hand and overtreatment with mineralocorticoids on the other hand. 224 
The antagonistic properties of progesterone on the human, rat and sheep mineralocorticoid receptor 225 
have been previously described. [9,11-15] A 50% inhibition of the maximum transactivation of the 226 
mineralocorticoid receptor is caused by progesterone concentrations between 2 to 11 nmol/l.[9,16-18] 227 
The inhibitory effect of progesterone described in our study is in line with those described in the 228 
studies mentioned above. Minor differences between the results of those studies may be explained by 229 
different cells and different luciferase constructs used.  230 
The effect of slightly elevated 17OHP concentrations on the hMR have been studied previously.[9] 231 
The previously reported concentration of 135 nmol/l, causing a 50% inhibition of transactivation of 232 
the hMR by a 10-9 mol/l aldosterone, is in line with the antagonistic effect of 17OHP on aldosterone 233 
mediated transactivation described in our study. In our study we evaluated the effect of even higher 234 
17OHP concentrations, as found in untreated or poorly controlled CAH patients. 235 
In contrast to the effect on transactivation the translocation to the nucleus seems not to be affected by 236 
17OHP or progesterone. The physiological human ligand of the hMR is aldosterone. After binding to 237 
aldosterone the hMR undergoes a conformational change and partial dissociation of the ligand binding 238 
complex occurs, leading to translocation of the hMR to the nucleus. Within the nucleus the activated 239 
receptors regulate transcription by different pathways including transactivation of target genes [19-23] 240 
Intracellular localization studies on the hMR have shown that in the absence of steroids the hMR is 241 
localized in the cytoplasm and in the nucleus, aldosterone causes a rapid nuclear accumulation of the 242 
hMR.[19,24-27] Binding of aldosterone to the hMR causes dissociation of several associated proteins 243 
from the receptor, followed by dimerization and finally nuclear translocation of the activated receptor. 244 
The translocation assay performed in this study shows a similar subcellular localization with a 245 
predominant localization of the hMR in the cytoplasm in the absence of steroids. Treatment of the 246 
COS-7 cells expressing the hMR-GFP construct with aldosterone causes a quick translocation of the 247 
hMR to the nucleus of the cells. However, different concentrations of 17OHP and progesterone in 248 
addition to a 10-10 mol/l aldosterone concentration do not have an impact on the translocation of the 249 
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hMR to the nucleus. This finding is in contrast to the described effects of hMR antagonists, such as 250 
spironolactone and eplenerone, which inhibit the translocation of the hMR to the nucleus.[19] 251 
The mechanism of the inhibition of the aldosterone mediated transactivation of the hMR by 252 
progesterone and 17OHP remains unclear. It has been shown that 17OHP has a relatively high 253 
binding affinity for the hMR.[9] Therefore, competitive binding of the hMR between 17OHP and 254 
aldosterone, such as in patients with poorly controlled CAH, is very likely. We showed that 17OHP 255 
does not inhibit the translocation of the hMR to the nucleus. We, therefore, hypothesize that the anti-256 
mineralocorticoid effect of 17OHP on the hMR is not due to an effect on the translocation of the hMR 257 
but might be caused by effects on the transcription after translocation to the nucleus. It has been 258 
suggested by Hellal-Levy et al. that binding of an antagonist to the hMR leads to an inactive 259 
conformation of the hMR. Due to instability this complex of the MR and its antagonist will not be 260 
converted into a transcriptionally active conformation. [20] This hypothesis may explain the 261 
antagonistic properties of 17OHP and progesterone on the hMR 262 
 263 
The MR p.Ile180Val SNP (rs5522) is one of the most frequent SNPs in the hMR with a frequency of 264 
10.2 % of the G allele in a European population (HapMap project, www.hapmap.org). The MR 265 
p.Ile180Val SNP has been associated with an increased hypertension risk. [28] As CAH patients have 266 
a tendency to develop elevated blood pressure, [29,30] the role of this SNP in CAH patients might be 267 
important with respect to their cardiovascular risk profile. We showed that the hMR p.Ile180Val SNP 268 
does not affect transactivation of the hMR by aldosterone. These findings are in line with the results 269 
by De Rijk et al.[31] In addition 17OHP has the same antagonistic effect on the hMR-I180V SNP as 270 
on the on the wild-type hMR. Thus, the results of this study do not explain the increased hypertension 271 
risk in p.Ile180Val.  272 
 273 
In conclusion, our study shows for the first time that neither androstenedione nor testosterone have a 274 
significant biological effect on the aldosterone-mediated transactivation of the hMR. In contrast, 275 
increased 17OHP and progesterone concentrations have an anti-mineralocorticoid effect due to an 276 
inhibition of aldosterone-mediated transactivation of the hMR. However, unlike hMR blockers, 277 
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neither 17OHP nor progesterone inhibits the translocation of the hMR to the nucleus. Further studies 278 
are needed to explain the mechanism of this inhibition of transactivation by 17OHP. 279 
280 
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Legends to figures and tables 387 
Figure 1. Dose response curves showing the transactivation of the hMR (wild type) and the hMR-388 
I180V SNP by different concentrations of Aldosterone using a luciferase assay. The results 389 
are expressed as the ratio of (firefly) luciferase and renilla (luciferase) activity. Data are 390 
means ± S.E.M for each concentration (n=9). 391 
Figure 2. The effect of different concentrations of 17OHP (A), progesterone (B), testosterone (C) and 392 
androstenedione (D) on the transactivation of hMR by 10-10 M aldosterone concentration. The 393 
transactivation activity of 10-10 M aldosterone was set as 1.0. Results are expressed as x fold 394 
transactivation of MMTV (firefly) luciferase (MMTV-luc). Data are means ± S.E.M for each 395 
concentration (n=9). Significant differences in transactivation between two concentrations 396 
closest to each other are indicated by an asterisks (p < 0.05).   397 
Figure 3. The effect of different concentrations of 17OHP on the transactivation of hMR by 10-10 M 398 
aldosterone concentration compared to the effect of different concentrations of 17OHP on the 399 
transactivation of the hMR-I180V SNP. The transactivation activity of 10-10 M aldosterone on 400 
the hMR (wild type) was set as 1.0. Results are expressed as x fold transactivation of MMTV 401 
(firefly) luciferase (MMTV-luc). Data are means ± S.E.M for each concentration (n=9). 402 
Figure 4 A. Cellular localization of the hMR without the presence of aldosterone and in the presence 403 
of aldosterone with or without different concentrations of 17OHP and progesterone. Cells 404 
were localized using confocal microscopy as 1. nuclear (black bars), 2. mainly nuclear (dark 405 
gray bars), 3. equal nuclear – cytoplasmic (light gray bars) and 4. mainly cytoplasmic (white 406 
bars) 407 
Figure 4 B. Images showing the four possible cellular localizations of the hMR: 1. nuclear, 2. mainly 408 
nuclear, 3. equal nuclear and cytoplasmic, 4. mainly cytoplasmic. Images are taken using a 409 
confocal microscope. Different images were taken showing DAPI staining, GFP  and a 410 
merged image. 411 
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Figure 4C. Cellular localization of the hMR-I180V without the presence of steroids and in the 412 
presence of aldosterone with or without different concentrations of 17OHP. Cells were 413 
localized using confocal microscopy as 1. nuclear (black bars), 2. mainly nuclear (dark gray 414 
bars), 3. equal nuclear – cytoplasmic (light gray bars) and 4. mainly cytoplasmic (white bars). 415 
Supplementary figure 1. Transactivational potential of the hMR construct versus the hMR-GFP 416 
construct evaluated by a luciferase assay. The results are expressed as the ratio of (firefly) 417 
luciferase to renilla (liciferase) activity corrected for pGL3 (transfection efficiency). Data are 418 
means ± S.E.M. (n=9). 419 
Supplementary table 1. Results of Bonferroni’s Multiple Comparison Test for all comparisons in the 420 
experiment evaluating the effect of different concentrations of 17OHP on the aldosterone 421 
mediated transactivation of the hMR 422 
Supplementary table 2. Results of Bonferroni’s Multiple Comparison Test for all comparisons in the 423 
experiment evaluating the effect of different concentrations of progesterone on the 424 
aldosterone mediated transactivation of the hMR 425 
Supplementary table 3. Results of Bonferroni’s Multiple Comparison Test for all comparisons in the 426 
experiment evaluating the effect of different concentrations of testosterone on the aldosterone 427 
mediated transactivation of the hMR 428 
Supplementary table 4. Results of Bonferroni’s Multiple Comparison Test for all comparisons in the 429 
experiment evaluating the effect of different concentrations of androstenedione on the 430 
aldosterone mediated transactivation of the hMR 431 
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